DVT MDM

Posted on by tydotphrase

MDM Templates

DVT — Discharge on Anticoagulation

Patient presents with unilateral lower extremity swelling and pain. They are well appearing and hemodynamically stable. No evidence of phlegmasia cerulea or alba dolens, no limb-threatening ischemia, and no signs of concurrent PE (no dyspnea, no chest pain, no tachycardia, no hypoxia).

Ultrasound confirms acute deep vein thrombosis. History, exam, and hemodynamic stability support outpatient management. Presentation is not consistent with phlegmasia, massive ilio-femoral DVT requiring catheter-directed therapy, or concurrent hemodynamically significant PE.

Plan: Anticoagulation initiated — apixaban 10 mg PO BID x 7 days then 5 mg PO BID, or rivaroxaban 15 mg PO BID x 21 days then 20 mg daily.
Disposition: Discharge with return precautions for worsening swelling, chest pain, dyspnea, or signs of bleeding. PCP follow-up within 48-72 hours for anticoagulation management.

Admit if: Concurrent PE symptoms, massive ilio-femoral clot, phlegmasia, hemodynamic instability, high bleeding risk requiring monitored anticoagulation initiation, inability to obtain outpatient anticoagulation.

DVT — Admit

Patient presents with extensive lower extremity DVT with concern for ilio-femoral extension / phlegmasia / concurrent PE symptoms. They demonstrate significant limb swelling, pain, and clinical concern beyond a routine distal DVT.

Presentation warrants inpatient management for monitored anticoagulation, possible advanced intervention, and evaluation for concurrent PE. History and exam raise concern for massive clot burden, phlegmasia, or hemodynamic compromise.

Plan: Heparin infusion initiated. Cross-sectional imaging if PE suspected.
Disposition: Admit. Vascular surgery or IR consultation for possible catheter-directed thrombolysis if ilio-femoral involvement or phlegmasia.

Negative Workup

Patient presents with unilateral leg swelling and pain. They are well appearing and hemodynamically stable. No lymphangitic spread, no fluctuance, and no evidence of cellulitis or compartment syndrome.

Ultrasound does not demonstrate acute deep vein thrombosis. History and exam lower suspicion for cellulitis, compartment syndrome, Baker’s cyst rupture, or lymphedema with acute complication.

Plan: Symptomatic management.
Disposition: Discharge with return precautions for worsening swelling, redness, or dyspnea. If clinical suspicion was moderate-to-high despite negative ultrasound, repeat ultrasound in 5-7 days.

Clinical Education

Anticoagulation Selection

DOACs are now first-line for most DVTs, replacing the warfarin/LMWH bridge per ACCP 2021 guidelines.[1]

Agent Dose Pearl
Apixaban (Eliquis) 10 mg PO BID x 7 days, then 5 mg PO BID Safe in renal impairment (no dose adjustment needed). Lowest bleeding risk of DOACs. Preferred in CKD.[2]
Rivaroxaban (Xarelto) 15 mg PO BID x 21 days, then 20 mg daily Avoid if CrCl <30. Once-daily maintenance dosing = good compliance.[3]
Enoxaparin (Lovenox) 1 mg/kg SubQ q12h Weight-based, NO cap on dosing. Do not use q24h dosing in obese patients. Bridge to warfarin if needed.[4]

Cancer-associated DVT: LMWH or DOACs (apixaban/rivaroxaban preferred over edoxaban/dabigatran due to lower GI bleeding risk). Avoid DOACs in GI or GU malignancy per ISTH guidance.[1]

Age-Adjusted D-dimer

Age-adjusted D-dimer cutoff: age x 10 for patients >50. Example: a 75-year-old’s cutoff is 750 ng/mL (not the standard 500). This approach reduces false-positive D-dimers in elderly patients by ~30% without missing clinically significant VTE.[5]

Isolated Calf Vein DVT

Isolated distal (calf) DVTs are a gray zone. Up to 25% propagate proximally in hospitalized or post-surgical patients, but rates are lower in ambulatory outpatients. Two management strategies are acceptable: serial ultrasound surveillance at 1 week, or empiric anticoagulation. Anticoagulation is reasonable if the patient has cancer, prior VTE, or is immobilized. Surveillance is reasonable in low-risk ambulatory patients with a small clot.[1]

Superficial Thrombophlebitis

Most cases are managed conservatively: warm compresses, elevation, NSAIDs (topical or oral), and compression stockings. However, superficial thrombophlebitis within 3 cm of the saphenofemoral junction carries a meaningful risk of DVT extension — consider anticoagulation.[6]

Fondaparinux 2.5 mg SubQ daily x 45 days reduced VTE progression and symptomatic DVT/PE in the CALISTO trial. Consider for large (>5 cm) or symptomatic superficial thrombophlebitis.[6]

Phlegmasia

Phlegmasia alba dolens: Massive ilio-femoral DVT causing a painful, white, edematous limb. The limb is swollen but perfused. Treat with heparin and elevation; consider catheter-directed thrombolysis for limb salvage.

Phlegmasia cerulea dolens: Progression to venous gangrene — the limb is blue, tensely edematous, and pulseless. This is a limb- and life-threatening emergency. Emergent heparin, surgical thrombectomy or catheter-directed thrombolysis, and possible fasciotomy. Mortality is 20-40%.[7]

References

  1. Stevens SM et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline. Chest. 2021;160(6):e545-e608. PubMed
  2. Agnelli G et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism (AMPLIFY). N Engl J Med. 2013;369(9):799-808. PubMed
  3. Bauersachs R et al. Oral Rivaroxaban for Symptomatic Venous Thromboembolism (EINSTEIN-DVT). N Engl J Med. 2010;363(26):2499-2510. PubMed
  4. Nutescu EA et al. Low-Molecular-Weight Heparins in Renal Impairment and Obesity. Ann Pharmacother. 2009;43(6):1064-1083. PubMed
  5. Righini M et al. Age-Adjusted D-Dimer Cutoff Levels to Rule Out Pulmonary Embolism (ADJUST-PE). JAMA. 2014;311(11):1117-1124. PubMed
  6. Decousus H et al. Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs (CALISTO). N Engl J Med. 2010;363(13):1222-1232. PubMed
  7. Chinsakchai K et al. Trends in Management of Phlegmasia Cerulea Dolens. Vasc Endovasc Surg. 2011;45(1):5-14. PubMed

Leave a comment